Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc. is a recognized specialty pharmaceutical company that uses state-of-the-art, cGMP compliant facilities to develop, manufacture, and market injectable and inhalation products. Amphastar and its subsidiaries each have their own distinct focus that they skillfully bring together to meet the varied needs of the pharmaceutical industry. We currently produce approximately 15 injectable products while we continue to develop a portfolio of generic and branded products that target large markets with high technical barriers to entry. Amphastar’s long-standing relationship with the major group purchasing organizations and drug wholesalers in the U.S. enables it to establish significant market share upon the introduction of its new products.
Company Growth (employees)
Rancho Cucamonga, US
Size (employees)
1,460 (est)
Amphastar Pharmaceuticals was founded in 1996 and is headquartered in Rancho Cucamonga, US

Amphastar Pharmaceuticals Office Locations

Amphastar Pharmaceuticals has an office in Rancho Cucamonga
Rancho Cucamonga, US (HQ)
11570 6th St

Amphastar Pharmaceuticals Data and Metrics

Amphastar Pharmaceuticals Financial Metrics

Amphastar Pharmaceuticals's revenue was reported to be $255.2 m in FY, 2016 which is a 1% increase from the previous period.
$, USD

Revenue (FY, 2016)

255.2 m

Revenue growth (FY, 2015 - FY, 2016), %


Gross profit (FY, 2016)

104.2 m

Gross profit margin (FY, 2016), %


Net income (FY, 2016)

10.5 m

EBIT (FY, 2016)

15.7 m

Market capitalization (23-Jun-2017)

813.7 m

Closing share price (23-Jun-2017)


Cash (31-Dec-2016)

72.4 m
Amphastar Pharmaceuticals's current market capitalization is $813.7 m.
$, USDFY, 2014FY, 2015FY, 2016


210.5 m251.5 m255.2 m

Revenue growth, %


Cost of goods sold

159.2 m174.2 m151 m

Gross profit

51.3 m77.3 m104.2 m

Gross profit Margin, %


Sales and marketing expense

5.6 m5.5 m5.5 m

R&D expense

28.4 m37.1 m41.2 m

General and administrative expense

34.8 m41.5 m41.8 m

Operating expense total

69.2 m84.2 m88.5 m


(18 m)(6.9 m)15.7 m

EBIT margin, %


Interest expense

(609 k)(987 k)(1 m)

Interest income

243 k315 k270 k

Pre tax profit

(18.1 m)(10.4 m)14.9 m

Income tax expense

(7.4 m)(7.6 m)4.4 m

Net Income

(10.7 m)(2.8 m)10.5 m
$, USDY, 2012Y, 2013FY, 2014FY, 2015FY, 2016


50.2 m53.6 m67.8 m66.1 m72.4 m

Accounts Receivable

22.9 m33.2 m26.8 m


118.4 m

Current Assets

198 m175.9 m184.1 m


138.3 m142.2 m152.9 m


42.6 m39.9 m50.3 m

Total Assets

389.4 m390.1 m427.7 m

Accounts Payable

10.2 m13.9 m16.2 m

Current Liabilities

62.6 m60 m60.6 m

Additional Paid-in Capital

220.7 m247.8 m283.1 m

Retained Earnings

63.1 m60.3 m70.9 m

Total Equity

295.5 m329.3 m

Financial Leverage

1.3 x1.3 x
$, USDFY, 2014FY, 2015FY, 2016

Net Income

(10.7 m)(2.8 m)10.5 m

Depreciation and Amortization

12 m

Accounts Receivable

1.2 m6.4 m


9.1 m(9.7 m)

Accounts Payable

7 m

Cash From Operating Activities

14.2 m(1.8 m)38.6 m

Purchases of PP&E

(18.7 m)

Cash From Investing Activities

(39.8 m)(39.5 m)

Long-term Borrowings

(8.2 m)(14.7 m)

Cash From Financing Activities

32.1 m7.1 m

Interest Paid

2.6 m

Income Taxes Paid

436 k3.4 m
Y, 2016

Financial Leverage

1.3 x

Amphastar Pharmaceuticals Operating Metrics

Amphastar Pharmaceuticals's Facilities was reported to be 5 in FY, 2016
FY, 2016





Amphastar Pharmaceuticals Market Value History

Amphastar Pharmaceuticals Revenue Breakdown

Amphastar Pharmaceuticals Median Salaries

Source: 12 public H-1B filings from Amphastar Pharmaceuticals

Amphastar Pharmaceuticals Online and Social Media Presence

Amphastar Pharmaceuticals News and Updates

Amphastar Pharmaceuticals Company Life and Culture

You may also be interested in